About US
Contact us
-
Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patientsA new study examines whether recent changes in the use of anemia drugs for patients on dialysis have contributed to changes in rates of death or cardiovascular events. The findings, which appear in an2016/2/29
-
New report explores strategies involved in developing and commercializing FDC productsFixed dose combination (FDC) products, which have been around for many years, can have both clinical and commercial advantages. Successful FDC products require thoughtful planning, beginning early in2016/2/29
-
Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs FundBack in August, the National Institute of Health and Care Excellence (NICE) said it would take the reins of England's Cancer Drugs Fund (CDF) in light of the fund's continued financial problems. Now t2016/2/29
-
Pfizer receives FDA approval for Xeljanz XR to treat rheumatoid arthritisPfizer has received the US Food and Drug Administration (FDA) approval for its Xeljanz XR (tofacitinib citrate) extended-release tablets for the treatment of rheumatoid arthritis (RA). Xeljanz XR is2016/2/26
-
Myriad Genetics expands research collaborations with AbbVie, Tesaro and MerckMyriad Genetics has expanded collaboration with AbbVie to accelerate development of the latter's investigational PARP inhibitor, veliparib. The companion diagnostics (CDx) research collaboration buil2016/2/26
-
Bayer sees new med Kovaltry as just one piece of its hemophilia puzzleEarlier this week,Bayernabbed an EU approval for a new, longer-lasting hemophilia med, Kovaltry. But the company isn't expecting all of the patients on stalwart treatment Kogenate to jump ship for the2016/2/25
-
Sanofi cans Auvi-Q marketing deal, putting injector pen's future in limboSanofi ($SNY) is in the process of cleaning house--and its anaphylaxis remedy, Auvi-Q, is next on the list of things to go. As PDL BioPharma ($PDLI) CEO John McLaughlin said earlier this week on his2016/2/25
-
Pfizer workers, retirees face big tax bills from $160B Allergan dealBig-time Pfizer ($PFE) investors are no doubt prepared for the tax hit from its forthcoming merger with Allergan ($ACT). But smaller shareholders, including current and retired employees, could face t2016/2/24
-
Prosecutors raid Novartis South Korea in kickbacks probeNovartis ($NVS) is facing another regulatory pickle in Asia. After a Japanese data scandal forced the company's unit there into temporary suspension last year, South Korean prosecutors have targeted t2016/2/24
-
US FDA grants breakthrough status for Novartis' PKC412 to treat FLT3-mutated AMLThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Novartis' investigational drug, PKC412 (midostaurin), to treat FLT3-mutated acute myeloid leukaemia (AML) in2016/2/23